Source comparison
Comparison of CJC-1295 Variants and Metabolic Profiles
Native GHRH (1-29) 6–8 minutes None DPP-4 degradation + renal filtration Continuous infusion or multiple daily Pulsatile (short-lived) Modified GRF (1-29) / CJC-1295 no DAC 30–60 minutes DPP-4 resistant but rapid renal clearance 2–3 times daily Pulsatile (ampl
This comparison does not assign a generated winner or score.
- Native GHRH (1-29)
- 6–8 minutes
- None
- DPP-4 degradation + renal filtration
- Continuous infusion or multiple daily
- Pulsatile (short-lived)
- Modified GRF (1-29) / CJC-1295 no DAC
- 30–60 minutes
- DPP-4 resistant but rapid renal clearance
- 2–3 times daily
- Pulsatile (amplified but brief)
- CJC-1295 with DAC
- 5–7 days
- Covalent (via MPA linker)
- Slow dissociation → renal (60%) + hepatic (40%)
- Twice weekly
- Pulsatile (sustained amplitude increase)
- CJC-1295 in renal impairment (eGFR <60)
- 8–10 days
- Reduced renal clearance shifts burden to hepatic
- Once weekly or extended interval
- Pulsatile (risk of accumulation)
- CJC-1295 + Ipamorelin
- 5–7 days (CJC) / 2 hours (Ipamorelin)
- CJC binds; Ipamorelin does not
- CJC as above; Ipamorelin cleared renally within 4–6 hours
- CJC twice weekly + Ipamorelin daily or BID
- Synergistic pulse amplification